Physician profile
Irving L Wolfe
NPI 1740250489
$5,825.18
in general payments reported to CMS, 2019-2025
27 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $819 · 2021: $969 · 2022: $980 · 2023: $884 · 2024: $1,011 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.52 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,311.88 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $597.32 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Lundbeck LLC | $477.33 | 2021-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $391.51 | 2019-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $329.48 | 2019-2022 | |
| Pfizer INC. | $313.53 | 2021-2025 | |
| Allergan, INC. | $299.94 | 2019-2021 | |
| Amgen INC. | $293.24 | 2019-2022 | |
| Sk Life Science, INC. | $260.43 | 2020-2025 | |
| Tanabe Pharma America, INC. | $210.65 | 2021-2025 | Radicava |
| Eisai INC. | $205.12 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $190.23 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $148.97 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $148.77 | 2022 | |
| Argenx US, INC. | $106.66 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $99.56 | 2020-2021 | |
| Ge Healthcare | $91.11 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $74.64 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $56.32 | 2025 | |
| Biogen, INC. | $41.20 | 2020-2021 | |
| Octapharma USA, INC. | $36.05 | 2022-2025 | Octagam Immune Globulin (Human) |
| Ucb, INC. | $30.78 | 2024 | Zilbrysq, Rystiggo |
| Almatica Pharma LLC | $30.15 | 2022-2023 | Gralise |
| Axsome Therapeutics, INC. | $27.93 | 2025 | Symbravo |
| Celgene Corporation | $19.81 | 2023 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $18.90 | 2021 | |
| Harmony Biosciences LLC | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irving Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.